Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACRS NASDAQ:CADL NASDAQ:GYRE NASDAQ:MOLN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACRSAclaris Therapeutics$4.50$4.44$1.34▼$5.15$628.47M0.761.22 million shs4.32 million shsCADLCandel Therapeutics$8.31$7.57$4.35▼$9.57$608.87M-0.491.87 million shs8.19 million shsGYREGyre Therapeutics$6.25$6.78$5.44▼$9.42$606.44M1.9184,110 shs85,723 shsMOLNMolecular Partners$3.82$4.08$3.41▼$5.36$154.25M1.074,585 shs1,041 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACRSAclaris Therapeutics0.00%+4.17%-0.44%+25.70%+210.34%CADLCandel Therapeutics0.00%-2.92%+4.01%+66.53%+74.95%GYREGyre Therapeutics0.00%+5.40%+3.14%-11.22%-22.55%MOLNMolecular Partners0.00%-2.28%-4.86%-13.22%+3.78%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACRSAclaris Therapeutics$4.50$4.44$1.34▼$5.15$628.47M0.761.22 million shs4.32 million shsCADLCandel Therapeutics$8.31$7.57$4.35▼$9.57$608.87M-0.491.87 million shs8.19 million shsGYREGyre Therapeutics$6.25$6.78$5.44▼$9.42$606.44M1.9184,110 shs85,723 shsMOLNMolecular Partners$3.82$4.08$3.41▼$5.36$154.25M1.074,585 shs1,041 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACRSAclaris Therapeutics0.00%+4.17%-0.44%+25.70%+210.34%CADLCandel Therapeutics0.00%-2.92%+4.01%+66.53%+74.95%GYREGyre Therapeutics0.00%+5.40%+3.14%-11.22%-22.55%MOLNMolecular Partners0.00%-2.28%-4.86%-13.22%+3.78%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACRSAclaris Therapeutics 3.13Buy$11.50155.56% UpsideCADLCandel Therapeutics 2.56Moderate Buy$18.00116.61% UpsideGYREGyre Therapeutics 2.00Hold$17.00172.00% UpsideMOLNMolecular Partners 2.25Hold$8.38119.24% UpsideCurrent Analyst Ratings BreakdownLatest MOLN, ACRS, GYRE, and CADL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/2/2026ACRSAclaris Therapeutics Lifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$13.006/1/2026ACRSAclaris Therapeutics Lifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy5/15/2026CADLCandel Therapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold5/11/2026GYREGyre Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D) ➝ Sell (D-)5/5/2026ACRSAclaris Therapeutics Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$7.00 ➝ $11.005/5/2026ACRSAclaris Therapeutics GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$12.005/4/2026ACRSAclaris Therapeutics GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy4/29/2026ACRSAclaris Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$8.00 ➝ $10.004/22/2026MOLNMolecular Partners HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$13.004/20/2026CADLCandel Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026CADLCandel Therapeutics Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight(Data available from 6/22/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACRSAclaris Therapeutics$7.83M80.26N/AN/A$0.85 per share5.29CADLCandel TherapeuticsN/AN/AN/AN/A$0.95 per shareN/AGYREGyre Therapeutics$116.59M5.20$0.22 per share28.13$1.48 per share4.22MOLNMolecular Partners$5.65M27.30N/AN/A$2.40 per share1.59Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACRSAclaris Therapeutics-$64.92M-$0.56N/AN/AN/A-832.58%-55.89%-38.49%8/6/2026 (Estimated)CADLCandel Therapeutics-$38.18M-$0.98N/AN/AN/AN/A-60.42%-41.33%8/13/2026 (Estimated)GYREGyre Therapeutics$5.03M-$0.09N/AN/AN/A-5.44%3.13%2.67%8/10/2026 (Estimated)MOLNMolecular Partners-$74.41M-$1.94N/AN/AN/AN/A-66.62%-54.85%8/24/2026 (Estimated)Latest MOLN, ACRS, GYRE, and CADL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026CADLCandel Therapeutics-$0.2958-$0.14+$0.1558-$0.14N/AN/A5/11/2026Q1 2026MOLNMolecular Partners-$0.4340-$0.45-$0.0160-$0.44N/AN/A5/7/2026Q1 2026ACRSAclaris Therapeutics-$0.16-$0.15+$0.01-$0.15$1.32 million$2.00 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthACRSAclaris TherapeuticsN/AN/AN/AN/AN/ACADLCandel TherapeuticsN/AN/AN/AN/AN/AGYREGyre TherapeuticsN/AN/AN/AN/AN/AMOLNMolecular PartnersN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACRSAclaris TherapeuticsN/A4.034.03CADLCandel Therapeutics0.3428.0528.05GYREGyre TherapeuticsN/A4.644.06MOLNMolecular PartnersN/A9.439.43Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACRSAclaris Therapeutics98.34%CADLCandel Therapeutics13.93%GYREGyre Therapeutics23.99%MOLNMolecular Partners26.55%Insider OwnershipCompanyInsider OwnershipACRSAclaris Therapeutics4.80%CADLCandel Therapeutics14.30%GYREGyre Therapeutics9.50%MOLNMolecular Partners5.93%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACRSAclaris Therapeutics100139.66 million132.96 millionOptionableCADLCandel Therapeutics6073.27 million62.79 millionOptionableGYREGyre Therapeutics4097.03 million87.81 millionNo DataMOLNMolecular Partners18040.38 million37.98 millionNot OptionableMOLN, ACRS, GYRE, and CADL HeadlinesRecent News About These CompaniesMolecular Partners Holds Presentations at ASCO and SNMMI 2026 on DLL3-Targeting Radio-DARPin MP0712, Now Dosing Patients in Phase 1May 30, 2026 | globenewswire.comMolecular Partners to Present at TD Cowen's 7th Annual Oncology Innovation SummitMay 26, 2026 | globenewswire.comMolecular Partners Reports Financial Results and Highlights for Q1 2026, with Clinical Studies Initiated on MP0712 and MP0317May 12, 2026 | globenewswire.comMolecular Partners to hold oral presentations on DLL3-targeting Radio-DARPin candidate MP0712 at multiple upcoming scientific conferencesMay 4, 2026 | globenewswire.comMolecular Partners publishes Phase 1 MP0317 data in Nature Cancer demonstrating tumor-localized CD40 activation and tumor microenvironment remodelingMay 1, 2026 | globenewswire.comMolecular Partners presents three posters at AACR 2026, with new preclinical data for first Switch-DARPin T cell engager MP0632 and DLL3 Radio-DARPin MP0712April 19, 2026 | globenewswire.comMolecular Partners Announces all Board Proposals Approved, Clare Fisher Elected as New Board Member at Annual General MeetingApril 14, 2026 | globenewswire.comMolecular Partners AG Sponsored ADRApril 10, 2026 | edition.cnn.comMolecular Partners Publishes Invitation to Annual General Meeting 2026 and Proposes Clare Fisher for Election to its Board of DirectorsMarch 23, 2026 | globenewswire.comMolecular Partners Presents New Preclinical Data Highlighting Radio-DARPins' Amenability to Multiple IsotopesMarch 19, 2026 | globenewswire.comMolecular Partners to Hold Three Poster Presentations at AACR 2026March 17, 2026 | globenewswire.comMolecular Partners Reports Highlights and Financial Results for Full Year 2025March 12, 2026 | globenewswire.comMolecular Partners Signs Development Agreement with Eckert & Ziegler for Targeted Alpha RadiotherapeuticsFebruary 26, 2026 | finance.yahoo.comMolecular Partners Announces Participation in March Investor Conferences and Upcoming 2025 Financial ResultsFebruary 26, 2026 | globenewswire.comMolecular Partners AG (MOLN) Discusses Clinical Imaging and Dosimetry Data for DLL3 Targeting Radiotherapeutic MPO712 TranscriptFebruary 2, 2026 | seekingalpha.comMolecular Partners Announces Presentation of First Imaging and Dosimetry Data of DLL3-Targeting Radiotherapy MP0712 in Patients at TWC 2026February 2, 2026 | globenewswire.comWhy Molecular Partners AG’s (MOLN) Stock Is Up 6.99%January 23, 2026 | aaii.comAMolecular Partners (MOLN) Gets a Buy from LifeSci CapitalJanuary 22, 2026 | theglobeandmail.comMolecular Partners AG (MOLN) Presents at 44th Annual J.P. Morgan Healthcare Conference TranscriptJanuary 15, 2026 | seekingalpha.comMolecular Partners to Present at 44th Annual J.P. Morgan Healthcare ConferenceDecember 18, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSpaceX Gets the Attention, But These 4 Stocks Could Get the ReturnsBy Bridget Bennett | May 25, 20265 Stocks Winning the AI Race While Everyone Watches NVIDIABy Bridget Bennett | May 26, 2026The Smart Glasses Gold Rush Is Leaving Old-School Eyewear BehindBy Jeffrey Neal Johnson | May 24, 20265 Under-the-Radar AI Stocks to Watch in JuneBy Thomas Hughes | May 31, 20263 Penny Stocks Under $5 Backed by Real Revenue GrowthBy Chris Markoch | June 20, 2026MOLN, ACRS, GYRE, and CADL Company DescriptionsAclaris Therapeutics NASDAQ:ACRS$4.50 0.00 (0.00%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$4.31 -0.19 (-4.20%) As of 06/18/2026 05:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.Candel Therapeutics NASDAQ:CADL$8.31 0.00 (0.00%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$8.37 +0.06 (+0.72%) As of 06/18/2026 07:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.Gyre Therapeutics NASDAQ:GYRE$6.25 0.00 (0.00%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$6.24 -0.01 (-0.24%) As of 06/18/2026 04:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Gyre Therapeutics, Inc., a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases. In addition, it advances a product pipeline in China, including Pirfenidone, for dermatomyositis interstitial lung disease, systemic sclerosis-associated interstitial lung disease, and pneumoconiosis, as well as for diabetic kidney disease; and product candidates for acute-on-chronic liver failure, chronic obstructive pulmonary disease, and pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California.Molecular Partners NASDAQ:MOLN$3.82 0.00 (0.00%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$3.85 +0.03 (+0.76%) As of 06/18/2026 07:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia. It also develops Switch-DARPin platform, a multispecific cKIT x CD16a x CD47 Switch-DARPin program for targeted and conditional immune cell activation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has license and research collaboration agreements with Novartis Pharma AG to develop DARPin-conjugated radioligand therapies; and collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/15 - 06/19 Applied Materials Stock Looks Pricey—Can AI Demand Justify the Rally? Satellogic Is Tiny But Its Revenue Growth Is Hard to Ignore Aehr Spikes on New Order, But Has Stock Gotten Ahead of Itself? Why Kroger’s Pullback Could Be a Gift for Patient Investors Credo Technologies Accelerates AI—Its Stock Price Will Follow Why Rocket Lab’s Nasdaq-100 Moment Could Change the Story Why Palantir’s Google Cloud Deal Could Change the Debate Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
